LINC00665: An Emerging Biomarker for Cancer Diagnostics and Therapeutics

Abstract

Long intergenic noncoding RNA 00665 (LINC00665) is located on human chromosome 19q13.12. LINC00665 was upregulated in eighteen cancers and downregulated in two cancers. LINC00665 not only inhibits 25 miRNAs but also directly affects the stability of ten protein-coding genes. Notably, LINC00665 also encodes a micro-peptide CIP2A-BP that promotes triple-negative breast cancer progression. LINC00665 can participate in five signaling pathways to regulate cancer progression, including the Wnt/β-catenin signaling pathway, TGF-β signaling pathway, NF-κB signaling pathway, PI3K/AKT signaling pathway, and MAPK signaling pathway. Aberrant expression of LINC00665 in breast cancer, gastric cancer, and hepatocellular carcinoma can be used for disease diagnosis. In addition, aberrant expression of LINC00665 is closely associated with clinicopathological features and poor prognosis of various cancers. LINC00665 is closely associated with the effects of anticancer drugs, including gefitinib and cisplatin in non-small cell lung cancer, gemcitabine in cholangiocarcinoma, and cisplatin-paclitaxel in breast cancer. This work systematically summarizes the diagnostic and prognostic values of LINC00665 in various tumors, and comprehensively analyzes the molecular regulatory mechanism related to LINC00665, which is expected to provide clear guidance for future research.

Novel Insights into miR-944 in Cancer

“…CircRNAs are a new class of regulatory RNAs with a covalent closed-loop structure [ 52 ]. Long non-coding RNA (lncRNA) is a non-coding RNA with a length of more than 200 nt that can regulate transcription, epigenetic modification, and translation [ 53 ]. CircRNAs, lncRNAs, and miRNAs constitute a ceRNA regulatory network to regulate downstream protein-coding gene expression [ 54 ].…”

Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives

“…The fact that gemcitabine plus cisplatin is widely used in a standard first-line chemotherapy regimen in patients with unresectable cholangiocarcinoma [ 30 ] suggests a potential relevance of CIP2A as a novel molecular target in this disease. Of note, these findings are further supported by the fact that the long intergenic non-coding RNA 00665 (LINC00665), which encodes a micropeptide CIP2A-BP [ 31 ], has been reported to promote the gemcitabine resistance of cholangiocarcinoma cells [ 32 ]. Moreover, CIP2A downregulation has been found to increase the sensitivity of lung cancer cells to cisplatin [ 33 ] and SN-38 (an active metabolite of irinotecan) [ 34 ], suggesting that it could also have relevance in re-sensitizing cholangiocarcinoma cells to these treatments.…”

Construction of a cuproptosis‐related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients

“…Due to the characteristics of tissue specificity, high stability, abundance, and species conservation, lncRNAs have been identified as a possible diagnostic and prognostic biomarker in the clinical management of cancer 22 . Additionally, lncRNAs are also associated with tumor metabolism, tumor microenvironment, and drug resistance, 23 consequently recognized as potential cancer drug targets 24,25 …”

“… 22 Additionally, lncRNAs are also associated with tumor metabolism, tumor microenvironment, and drug resistance, 23 consequently recognized as potential cancer drug targets. 24 , 25 …”

“…22 Additionally, ln-cRNAs are also associated with tumor metabolism, tumor microenvironment, and drug resistance, 23 consequently recognized as potential cancer drug targets. 24,25 Programmed cell death is an essential physiological and pathological process to remove superfluous or damaged cells to ensure healthy development and tissue homeostasis, 26 including apoptosis, autophagy, pyroptosis, ferroptosis, and necroptosis. [27][28][29] Recently, a novel cell death pathway was reported by Tsvetkov et al 30 Cuproptosis is defined as the copper-dependent death of the cells, where the copper binds directly to the lipoylated components of the tricarboxylic acid (TCA) cycle.…”